Description:
Available For: Exclusive/Non-Exclusive/Option
<h2>Summary</h2>
{{start}} Clinicians at Moorfields Eye Hospital, the leading provider of eye health services in Europe have developed software which is able to quantify dry eye in a patient. The software quantifies the number, distribution and size of fluorescein staining allowing screening, diagnosis and monitoring of the dry eye and other eye diseases. {{end}}
<h2>The Technology and its Advantages</h2>
{{start}} Corneal staining with fluorescein is used to diagnose and manage common eye problems from dry eyes and allergic eye disease to corneal ulcers. Currently, the surface damage to the dry eye is analysed by the consultant and compared to one of the grading scales broadly used in the clinic. Discrepancies in grading may be due to the same consultant assessing the corneal staining at different times, or the same staining pattern being classified into different groups by different consultants. This causes problems with diagnosis and monitoring of patient’s response to treatment but is especially problematic in evaluating the dry eye products in clinical trials.
The software developed by the consultants at Moorfields Eye Hospital provides an objective measurement of corneal staining which can assist consultants in diagnosing and managing the condition and could be used for quantification of dry eye in clinical trials. The software analyses the image of the stained eye and measures different patterns and distributions of blemishes to assist the ophthalmologist in diagnosing and monitoring dry eye and other conditions. The results are displayed to the consultant in the preferred graphical display allowing objective assessment and recording of the staining pattern.
Corneal images may be obtained and analysed at a site remote to the image capture, providing greater flexibility for acquisition and analysis, and the measurements can be obtained without the need of a consultant in the first instance.
Accurate and objective quantification of dry eye enables clear clinical end point making it an invaluable tool in clinical trials. {{end}}
<h2>Market Opportunity</h2>
{{start}} Dry Eye Syndrome, also known as keratoconjunctivitis sicca, is the most common eye disease with over 267 million cases estimated in 2016 across the major markets: US, France, Germany, Italy, Spain, UK, Japan, and China (Global Data). A number of pipeline products are currently undergoing clinical trials, with over 20 products being currently at preclinical stages. Corneal staining with fluorescein is used to diagnose and manage common eye problems from dry eyes and allergic eye disease to corneal ulcers.
An objective measurement of corneal staining and severity of the disease can assist consultants in diagnosing and managing the condition and could be used for quantification of in clinical trials. {{end}}
<h2>Intellectual Property Status</h2>
Proprietary software
<h2>Further Information</h2>
Please contact Dr Maria Mastrogiannaki, Business Manager | T: +44 (0)20 7679 9000 | E: m.mastrogiannaki@uclb.com